Latest Breaking News On - Lank center - Page 1 : vimarsana.com

Dana-Farber Uncovers Patient-Physician Experience Disparities

Dana-Farber researchers uncover disparities in liv

Wave of Antibody-Drug Conjugates Poised to Change Treatment Paradigms Across Multiple Cancers

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

- Updated safety and efficacy results on SRK-181 will be featured in an oral presentation on Monday, June 3rd, at 1:50 p.m CDT/2:50 p.m. EDT - Company will host conference call to discuss the data on...

Health care professionals celebrate 'milestone' FDA approval for HER2-positive solid tumors

An analysis of global online conversations among health care professionals on social media in April revealed tremendous enthusiasm about FDA approval of a treatment for adults with advanced HER2-positive solid tumors. The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu; AstraZeneca, Daiichi Sankyo) — a HER2-directed antibody-drug conjugate previously approved

Prior Abiraterone Strengthens Outcomes With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

Outcome improvements with lutetium Lu 177 vipivotide tetraxetan vs ARPI change favored prior treatment with abiraterone vs enzalutamide in mCRPC.

New Cancer 'Missile' Drugs May Be More Effective Than Traditional Chemotherapy

Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care

Paul V. Viscuse, MD, spotlights key data from the 2024 Genitourinary Cancers Symposium in bladder cancer and renal cell carcinoma.

Do you know immunotherapy post-surgery improves overall survival for kidney cancer? Study finds

How to Talk to Kids When a Parent Has Cancer